Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NVIDIA : Invites Healthcare Startup Submissions to Access UK's Most Powerful Supercomputer

09/22/2021 | 10:42am EDT

It takes major computing power to tackle major projects in digital biology - and that's why we're connecting pioneering healthcare startups with the U.K.'s most powerful supercomputer, Cambridge-1.

U.K. startups can now apply to harness the system, which is dedicated to advancing healthcare with AI and digital biology.

Since inaugurating Cambridge-1 in July, five founding partners have been tapping the supercomputer for projects in drug discovery, medical imaging and genomics. Peptone, a U.K. company collaborating with NVIDIA on AI-driven protein engineering, will also use Cambridge-1 for its work.

"The astounding parallelism embedded in NVIDIA processors allows us to run very dense, very complex simulations," said Peptone founder and CEO Kamil Tamiola. "We envision that computers will transform engineering and design in the protein space."

The first NVIDIA supercomputer designed and built for external research access, Cambridge-1 is an NVIDIA DGX SuperPOD powered by 80 NVIDIA DGX A100 systems, BlueField-2 DPUs and NVIDIA HDR InfiniBand networking. Running on 100 percent renewable energy, it's among the top 50 supercomputers in the world.

Giving startups access to the powerful system will help the companies bring their healthcare innovations to market faster, accelerating the evolution of drug discovery, genome sequencing and disease research.

Peptone Pushes the Frontier of Protein Engineering

Peptone, a member of the NVIDIA Inception program for AI and data science startups, aims to change the way protein drugs are engineered using unsupervised learning and reinforcement learning techniques. It plans to use Cambridge-1 to design antibodies that could help treat several inflammatory disorders.

Developed in collaboration with NVIDIA, Peptone's protein drug discovery engine enables scientists to search for protein variants that would be cost effective to manufacture and offer promising therapeutic properties. It's already in use for pre-clinical research.

The startup combines generative AI models, computational molecular physics and lab experiments to model unstructured proteins. Also called disordered proteins, these molecules lack a stable shape, making it extremely difficult to engineer drug compounds to bind with them.

Up to half the proteins in the human body are of this shape-shifting variety, including proteins involved in cancer, inflammatory diseases and neurodegenerative diseases like Parkinson's and Alzheimer's.

These proteins are challenging to study experimentally, so Peptone uses AI and complex simulations to study the link between molecular mutations and protein behavior. The company's researchers require powerful computational resources to help them iterate faster, mutate more of the simulated proteins and build a bigger library of promising drug molecules to test.

"We don't run one massive simulation, we run millions of short simulations. With many of these calculations running concurrently, we need to think about calculating events asynchronously to get the best performance from our system," said Tamiola. "For us, the A100 GPU was a breakthrough - because with the NVIDIA Ampere GPU architecture, it was so much easier to get this right."

Tamiola said the latest NVIDIA CUDA libraries helped Peptone reduce latency and "unlock that computational power" by compiling the team's standard C++ code to CUDA, allowing them to quickly port their algorithms to run on NVIDIA GPUs.

UK Startups: Apply for Cambridge-1 Access

Applications from U.K. healthcare startups for access to Cambridge-1 will be accepted here until December 30.

The selected companies, to be announced in early 2022, will also be invited to meet with the founding partners of the supercomputer - AstraZeneca, GSK, Guy's and St Thomas' NHS Foundation Trust, King's College London and Oxford Nanopore - and will gain access to NVIDIA Inception benefits including critical go-to-market support, training and technology.

Learn more about the capabilities of Cambridge-1, and about the NVIDIA Inception program, which includes more than 500 of the U.K.'s most dynamic AI startups.

Subscribe to NVIDIA healthcare news and follow NVIDIA Healthcare on Twitter.


Nvidia Corporation published this content on 22 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 14:41:05 UTC.

ę Publicnow 2021
10/15FOOD FOR THOUGHT : Startups Harness AI to Nurture the Future of Agriculture
10/14INSIDER SELL : Nvidia
10/14Coding platform GitLab valued at $14.9 billion in strong market debut
10/14LOOKS CAN BE PERCEIVING : Startups Build Highly Accurate Perception Software on NVIDIA DRI..
10/14Coding platform GitLab valued at $14.9 bln in strong market debut
10/14NVIDIA : But Can It Run ‘Crysis Remastered?' With GeForce NOW, Nearly Any Device Can
10/13GLOBAL MARKETS LIVE : LVMH, Blackrock, Qualcomm, Apple, Hasbro...
10/12NVIDIA : May Face Antitrust Investigation as EU Looks Into ARM Merger
10/12CLOUDY WITH A CHANCE OF AI : Data Scientists Develop Flood Detection for Early Warning
10/12NVIDIA : Concessions on ARM Merger Not Enough for EU
More news
Analyst Recommendations on NVIDIA CORPORATION
More recommendations
Financials (USD)
Sales 2022 25 758 M - -
Net income 2022 8 775 M - -
Net cash 2022 11 397 M - -
P/E ratio 2022 65,6x
Yield 2022 0,08%
Capitalization 546 B 546 B -
EV / Sales 2022 20,7x
EV / Sales 2023 18,1x
Nbr of Employees 18 975
Free-Float 62,0%
Duration : Period :
NVIDIA Corporation Technical Analysis Chart | NVDA | US67066G1040 | MarketScreener
Technical analysis trends NVIDIA CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 42
Last Close Price 218,62 $
Average target price 227,82 $
Spread / Average Target 4,21%
EPS Revisions
Managers and Directors
Jen Hsun Huang President, Chief Executive Officer & Director
Colette M. Kress Chief Financial Officer & Executive Vice President
William James Dally Chief Scientist & Senior Vice President-Research
Tony Tamasi Senior Vice President-Content & Technology
Debora Shoquist Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
BROADCOM INC.14.94%207 146
QUALCOMM, INC.-14.53%146 866